GMAB•benzinga•
Genmab Announces Japan Approval Of EPKINLY For Treating Relapsed/Refractory Follicular And Large B-Cell Lymphomas; First Subcutaneous T-Cell Engaging Bispecific Antibody Approved In Japan, U.S., EU For Dual Indication
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 20, 2025 by benzinga
Last updated: August 6, 2025 at 09:59 PM